real peptides FAQ

Reduce your dose to 0.75mg and pre-medicate with ondansetron 4mg orally 30 minutes before the next injection. Nausea results from melanocortin receptor activation in the brainstem chemoreceptor trigger zone. It's a central nervous system effect, not gastric irritation. Ondansetron blocks serotonin 5-HT3 receptors in the area postrema without interfering with PT-141's dopaminergic arousal mechanism. Most patients who experience nausea at 1.0mg tolerate 0.75mg without antiemetic support after the first two doses.

PT-141 is not intended for daily use. It's dosed on-demand before anticipated sexual activity. Daily administration increases nausea incidence and doesn't produce cumulative arousal benefit because melanocortin receptors don't require sustained agonism. Oxytocin can be used more frequently (2–3 times per week) for partnered activity without tolerance developing. For patients seeking sustained libido restoration, consider whether the root cause is hormonal (treatable with estrogen or testosterone) or neurological (treatable with PT-141).

P21 targets similar synaptic plasticity pathways at a fraction of Cerebrolysin's cost per dose. While Cerebrolysin contains multiple neurotrophic peptide fragments (giving it broader receptor activity), P21's focused mechanism on hippocampal LTP makes it a viable alternative for protocols specifically studying memory consolidation. Dihexa is another option. It activates hepatocyte growth factor (HGF) signaling, promoting synaptogenesis through a different receptor than Cerebrolysin's BDNF-mediated pathway.

Discard the vial. Do not use it. Peptide bonds begin denaturing above 8°C, and an 8-hour temperature excursion at 20–25°C can reduce potency by 30–50%. The solution may still appear clear, but molecular structure has been compromised. Our team at Real Peptides consistently advises researchers to treat any unrefrigerated reconstituted peptide as unusable regardless of visual appearance.

Mitochondrial adaptations induced by ERR agonism decay similarly to training-induced changes when the stimulus is removed. The Washington study tracked animals for 14 days post-treatment. Endurance capacity declined by approximately 40% within two weeks of cessation. This mirrors detraining physiology: mitochondrial density and oxidative enzyme content decrease when the transcriptional signal (training or pharmacological) stops. Maintaining adaptations likely requires continuous low-dose administration or transition to actual training to sustain ERR activation naturally.

Yes, but don't mix them in the same syringe. BPC-157 and TB-500 operate through different mechanisms (angiogenesis versus keratinocyte migration), so combining them isn't redundant. They address different bottlenecks in the healing cascade. Administer them as separate injections at different sites proximal to the injury. A 2024 case series published in Regenerative Medicine documented combination protocols in 18 patients with chronic wounds, reporting no adverse interactions and a mean 35% faster closure compared to single-peptide protocols. The only contraindication is cost. Running two peptides simultaneously doubles expense without always doubling benefit unless the wound is genuinely stalled at multiple phases.

Check three variables before concluding the peptide is ineffective: reconstitution sterility (bacterial contamination neutralises peptide activity), storage temperature (any excursion above 8°C denatures BPC-157 irreversibly), and application proximity (topical BPC-157 must be applied directly to the wound bed, not to intact skin surrounding the wound). If all three are correct and no improvement is visible after 14 days, the wound may have a bacterial biofilm preventing peptide penetration. This requires debridement or antimicrobial therapy before peptide protocols can work. BPC-157 doesn't replace infection management; it accelerates healing once infection is controlled.

For peptides with half-lives under 24 hours (like non-DAC CJC-1295 or Ipamorelin), administer the missed dose as soon as you remember and resume your regular schedule. For long-acting peptides like CJC-1295 with DAC (half-life 6–8 days), skipping one dose has minimal impact. Plasma levels remain elevated for days after the last injection. Do not double-dose to 'catch up'. Receptor saturation doesn't accelerate results and increases the risk of side effects like water retention or elevated fasting glucose.

Do not use it. Visible particulate matter indicates either incomplete dissolution (most likely if it appeared within 24 hours of reconstitution) or bacterial contamination (if it developed later). SS-LUP-332 should form a clear, colourless solution with no visible precipitate. If particles appeared immediately after mixing, your reconstitution technique may have been too aggressive. Violent shaking denatures peptides. If particles developed days later, contamination is the likely cause. Discard the vial and review your sterile technique.

Authentic batch-traceable QR codes link to web pages on the manufacturer's verified domain showing batch-specific data: synthesis date, testing date, purity results, and the testing laboratory's contact information. A QR code directing to a static PDF with no batch identification or one that fails to scan entirely suggests counterfeit packaging. Contact the supplier's listed customer service and request direct verification of the batch number. Legitimate manufacturers maintain searchable batch databases and can confirm authenticity within hours. If verification fails or the supplier can't be reached through listed contact methods, treat the product as counterfeit.

Dosages above 30 mg/kg in rodent models did not produce toxicity but also yielded no additional endurance benefit beyond the 10 mg/kg plateau. This suggests receptor saturation. Once ERRα and ERRγ are fully occupied, excess compound circulates without binding additional targets. No adverse events were documented at 50 mg/kg in short-term (7-day) trials, but prolonged high-dose administration hasn't been evaluated. The practical implication: dosing beyond the established ceiling wastes compound without improving outcomes.

Dose the compound at the standard 10 mg/kg range and maintain your existing training protocol. The Washington University study included a trained cohort that received SLU-PP-332 alongside continued exercise. These animals showed additive improvement (approximately 120% total endurance gain vs baseline), suggesting the compound doesn't interfere with training-induced adaptation. The mechanism supports this: ERR activation amplifies the transcriptional response to training stimulus rather than replacing it. Peak benefit likely occurs when both pharmacological receptor activation and physiological training stress converge.

Growth hormone secretagogues like MK 677 elevate ghrelin signaling, which increases appetite. This is the intended mechanism, not a side effect. The metabolic benefit comes from increased GH release, not appetite suppression. If appetite increase interferes with study objectives, consider switching to peptides targeting AMPK or insulin sensitivity pathways, which produce metabolic effects without ghrelin receptor activation.

Dose 60–90 minutes after the session, not before. Myostatin upregulation follows mechanical stress. Placing peak Follistatin-344 availability during the post-training window when myostatin is trying to limit satellite cell activation produces better outcomes than pre-dosing. Fasted training doesn't change the myostatin expression timeline.

Verify three factors before concluding non-response: reconstitution date (peptides in sterile water lose potency rapidly), injection proximity to injury site (subcutaneous administration >5cm from the affected ligament reduces local bioavailability significantly), and dosing timing relative to injury phase. BPC-157 acts primarily during the proliferative phase (days 14–56 post-injury). Administration during the inflammatory phase or late remodelling phase produces minimal effect because the cellular targets (fibroblasts, endothelial cells undergoing angiogenesis) are not yet active or have already completed their primary activity window. If all three factors are correct and response is still absent, consider TB-500 as an alternative or verify peptide purity through third-party assay.

Request the testing laboratory's full name and accreditation details. Legitimate labs proudly display ISO/IEC 17025 accreditation and provide verification on their websites. If the supplier can't produce this information within 24 hours, the CoA is likely fabricated using a generic template. Cross-reference the lab name against the International Laboratory Accreditation Cooperation member directory at ilac.org. Only accredited labs appear in this database. A supplier unwilling to provide verifiable testing documentation should be excluded from your procurement process immediately.

Single daily dosing at 100mcg post-training on training days is sufficient for most 3-day-per-week protocols. Given the 72-hour gap between sessions, maintaining plasma levels between workouts offers minimal added value. Myostatin suppression matters most in the 24–48 hours following stimulus when protein synthesis rates are elevated.

Use a validated cold-chain shipping container with temperature logging. Standard gel-pack coolers don't maintain 2–8°C reliably. Temperature can drift to 12–15°C within four hours. Purpose-built peptide transport systems like those from Pelican BioThermal or Credo maintain controlled refrigeration for 48–96 hours. Place a calibrated temperature logger inside the shipping container and verify temperature stayed within 2–8°C upon arrival. If temperature exceeded 8°C at any point during transport, the peptide should be discarded. We ship high-purity research peptides using validated cold-chain logistics for exactly this reason. Temperature control during transport is just as critical as storage.

The positive pressure created inside the vial forces peptide-laden solution back through the needle, contaminating the needle exterior and reducing dose accuracy. To prevent this: insert the needle through the stopper, invert the vial completely, draw the solution without injecting air first, and withdraw at a 45-degree angle. If you've already injected air, wipe the needle with an alcohol swab before injection to remove exterior contamination. But note that repeated air injection degrades the rubber stopper over time, increasing particulate contamination risk in subsequent draws.

Check the internal thermometer immediately when power returns. If the temperature stayed below 10°C throughout the outage, the peptide is likely salvageable for short-term use (within 7 days). If the temperature exceeded 10°C or you don't have temperature logging, discard the solution. Laboratory refrigerators with battery backup alarms exist specifically to prevent this scenario. Invest in one if you're storing high-value compounds. Our experience shows unmonitored temperature failures account for 30% of all peptide storage losses.